Day: July 25, 2024

Exceeded Fourth Quarter Operating Income Guidance Delivered Most Profitable Year in Company History Strong Fourth Quarter Adjusted Free Cash Flow Pulling Operating Income Target Forward 2 Years to Fiscal Year 2025 Authorized Share Repurchase Program PHILADELPHIA, July 25, 2024 (GLOBE NEWSWIRE) — Carpenter Technology Corporation (NYSE: CRS) (the “Company”) today announced financial results for the fiscal fourth quarter and year ended June 30, 2024. For the quarter, the Company reported operating income of $108.3 million, and earnings per diluted share of $1.85. Excluding special items discussed below, adjusted operating income was $125.2 million and adjusted earnings per diluted share was $1.82 for the current quarter. Fourth Quarter HighlightsDelivered $125.2 million of adjusted operating income, up 39 percent sequentially and...

Fast Track is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need Fast Track designation for Tonmya recognizes fibromyalgia as a serious condition impacting more than 10 million U.S. adults NDA submission on track for second half 2024 Tonmya has the potential to be the first new drug for treating fibromyalgia in more than 15 years CHATHAM, N.J., July 25, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia. Tonmya is a non-opioid,...

SHOEMAKERSVILLE, Pa., July 25, 2024 (GLOBE NEWSWIRE) — Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture (“CEA”), today announced that it will host a conference call to review second quarter 2024 results on Thursday, August 8, 2024 at 8:30 AM ET. A press release containing second quarter 2024 results will be issued before market open that same day. The conference call can be accessed live over the phone by dialing 1-800-267-6316 and entering the conference ID: HYFMQ2. The conference call will also be webcast live and archived on the corporate website at www.hydrofarm.com, under the “Investors” section. About Hydrofarm Holdings Group, Inc.Hydrofarm is a leading independent...

WEST LAFAYETTE, Ind., July 25, 2024 (GLOBE NEWSWIRE) — Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, on Thursday, August 8, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing:1-800-225-9448 (Domestic) 1-203-518-9708 (International) INOTIV (Conference ID)The live conference call webcast will be accessible in the Investors section of the Company’s web site and directly via the...

THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Dial-in InformationU.S. Dial-in Number: (888) 317-6003International Dial-in Number: (412) 317-6061Conference ID: 7023126 Replay InformationU.S. Dial-in Number: (877) 344-7529Replay International Dial-in Number: (412) 317-0088Conference ID: 3907883 The dial-in replay will be available for 7 days following the call. An audio webcast will be available online at www.lexpharma.com/events, with a webcast replay accessible for 14 days after the call. About Lexicon Pharmaceuticals Lexicon...

Nearing completion of enrollment, the SEISMiC Extension Phase 2b study in early cardiogenic shock patients is set to deliver new data WARRINGTON, Pa., July 25, 2024 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced an update of istaroxime in both clinical and business development. Istaroxime is a novel first-in-class therapy that is designed to improve systolic contraction and diastolic relaxation of the heart while also increasing blood pressure and maintaining or improving renal function. It has been studied in three positive Phase 2 trials enrolling patients with acute heart failure (AHF) and early cardiogenic shock. In line with previous guidance,...